Clinical Trial Update: Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of alfuzosin for voiding dysfunction in people with multiple sclerosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Alfuzosin (alfuzosin)

Snippet

Sponsor: Nova Scotia Health Authority | Conditions: Multiple Sclerosis, Bladder Dysfunction | Phase 2, Phase 3 | Status: TERMINATED